Euroscreen Announces the Completion of Research Agreement with GNF and Novartis
News Mar 28, 2007
Euroscreen and GNF will be engaged in research focused upon the development of therapeutic antibodies targeting G protein coupled receptors (GPCRs).
Commenting on the new research collaboration, Dr. Jean Combalbert, Euroscreen's CEO indicated, "Euroscreen has years of success in soliciting anti-GPCR antibodies, and more specifically, anti-GPCR antibodies with agonist or antagonist activities. This new deal is again demonstrating our great interest to anti-GPCR antibodies collaborations to develop therapeutic antibodies against relevant targets."
Combalbert continues, "Therapeutic antibodies are well recognized to provide excellent efficacy and rapid development time frames. This agreement with GNF and Novartis is a logical extension of our own strategy to develop new therapeutics for unmet medical needs. Both partners are combining their expertise and making commitments of resources to the collaboration."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE